Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Inspection Fees Face Tough Road In Congress As PhRMA Remains Opposed

Executive Summary

At user fee hearing, PhRMA’s Wheadon counters questions from Rep. Dingell, saying FDA already is receiving resources to conduct GMP inspections outside the U.S.

You may also be interested in...



FDA User Fee Bill Up For Final Senate Action After House Passage

Senate is last step before the bill goes to the president; Rep. Dingell laments that legislators were “closer than ever before” on a tracking agreement but did not quite make it.

GMP Carrots For Quality: FDA Considers Incentives To Adopt Quality Systems

The type of incentive remains under consideration, but one suggestion is a grading system similar to what restaurants receive from local health departments.

FDA Highlights Hands-On Approach To China Inspections In Budget Plan

The budget request targets an increase in pharmaceutical programs’ budget authority to boost the number of FDA staff focused on China’s manufacturing. The proposed $10 million increase, including $5.6 million to be allocated toward manufacturing, provides for additional inspections, educational efforts and inspectors in China.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS054195

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel